The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628
- von Minckwitz, Gunter
- Huang, Chiun-Sheng
- Mano, Max S
- Loibl, Sibylle
- Mamounas, Eleftherios P
- Untch, Michael
- Wolmark, Norman
- Rastogi, Priya
- Schneeweiss, Andreas
- Redondo, Andres
- Fischer, Hans H
- Jacot, William
- Conlin, Alison K
- Arce-Salinas, Claudia
- Wapnir, Irene L
- Jackisch, Christian
- DiGiovanna, Michael P
- Fasching, Peter A
- Crown, John P
- Wülfing, Pia
- Shao, Zhimin
- Rota Caremoli, Elena
- Wu, Haiyan
- Lam, Lisa H
- Tesarowski, David
- Smitt, Melanie
- Douthwaite, Hannah
- Singel, Stina M
- Geyer, Charles E
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- von Minckwitz, Gunter
- Huang, Chiun-Sheng
- Mano, Max S
- Loibl, Sibylle
- Mamounas, Eleftherios P
- Untch, Michael
- Wolmark, Norman
- Rastogi, Priya
- Schneeweiss, Andreas
- Redondo, Andres
- Fischer, Hans H
- Jacot, William
- Conlin, Alison K
- Arce-Salinas, Claudia
- Wapnir, Irene L
- Jackisch, Christian
- DiGiovanna, Michael P
- Fasching, Peter A
- Crown, John P
- Wülfing, Pia
- Shao, Zhimin
- Rota Caremoli, Elena
- Wu, Haiyan
- Lam, Lisa H
- Tesarowski, David
- Smitt, Melanie
- Douthwaite, Hannah
- Singel, Stina M
- Geyer, Charles E
- Titel
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- Ist Teil von
- The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Residual cancer after induction therapy for HER2-positive breast cancer is associated with a worse prognosis than no residual cancer. In a randomized trial, trastuzumab emtansine was superior to trastuzumab with respect to invasive disease–free survival.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1814017Titel-ID: cdi_hal_primary_oai_HAL_hal_02464524v1
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Anthracycline, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Agents, Immunological - therapeutic use, Biopsy, Breast cancer, Breast Neoplasms - drug therapy, Breast Neoplasms - metabolism, Breast Neoplasms - mortality, Breast Neoplasms - therapy, Cancer therapies, Chemotherapy, Chemotherapy, Adjuvant, Clinical trials, Cytotoxicity, Death, Disease-Free Survival, Endocrine therapy, Epidermal growth factor, ErbB-2 protein, Female, Humans, Immunotherapy, Invasiveness, Life Sciences, Lymphatic Metastasis, Maytansine - adverse effects, Maytansine - analogs & derivatives, Maytansine - therapeutic use, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Neoadjuvant Therapy, Neoplasm Metastasis, Neoplasm Staging, Neoplasm, Residual, Peripheral Nervous System Diseases - chemically induced, Radiotherapy, Receptor, ErbB-2 - metabolism, Surgery, Survival, Targeted cancer therapy, Trastuzumab, Trastuzumab - adverse effects, Trastuzumab - therapeutic use, Treatment Outcome, Young Adult